Prophylactic antiviral therapy for hepatitis B virus surface antigen‐positive patients with diffuse large B‐cell lymphoma treated with rituximab‐containing chemotherapy

We conducted a nationwide retrospective analysis of 116 hepatitis B virus (HBV) surface antigen (HBsAg)‐positive patients with diffuse large B‐cell lymphoma (DLBCL) and 278 HBsAg‐negative patients with DLBCL, as a control cohort, who received rituximab‐containing regimens as an induction chemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamauchi, Nobuhiko, Maruyama, Dai, Choi, Ilseung, Atsuta, Yoshiko, Sakai, Rika, Miyashita, Kazuho, Moriuchi, Yukiyoshi, Tsujimura, Hideki, Kubota, Nobuko, Yamamoto, Go, Igarashi, Tadahiko, Izutsu, Koji, Yoshida, Shinichiro, Kojima, Kensuke, Uchida, Toshiki, Inoue, Yoshiko, Tsukamoto, Norifumi, Ohtsuka, Eiichi, Suzuki, Sachiko, Inaguma, Yoko, Ichikawa, Satoshi, Gomyo, Hiroshi, Ushijima, Yoko, Nosaka, Kisato, Kurata, Mio, Tanaka, Yasuhito, Ueda, Ryuzo, Mizokami, Masashi, Kusumoto, Shigeru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088933/
https://www.ncbi.nlm.nih.gov/pubmed/33576088
http://dx.doi.org/10.1111/cas.14846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088933/
https://www.ncbi.nlm.nih.gov/pubmed/33576088
http://dx.doi.org/10.1111/cas.14846

Ejemplares similares